Biocon Aims to Develop Novel Cancer Treatments in India

Biocon Ltd, a leading biotech company based in Bangalore, intends to develop, manufacture, and market novel products, including monoclonal antibodies, for the treatment of head and neck cancer in India. According to the firm, monoclonal antibodies specifically target receptors overexpressed in tumor cells, offering an advantage over conventional therapies. With an estimated 700,000 new cancer cases in India every year, with 50% of them resulting in fatalities, and 230,000 cases linked to tobacco use, the need for effective treatments is pressing.

Key Takeaways:

• Biocon plans to develop and market novel products, including monoclonal antibodies, for the treatment of head and neck cancer in India.
• These treatments target receptors such as EGF-R, which are overexpressed in tumor cells, providing an advantage over conventional therapies.
• India has a significant burden of cancer, with 700,000 new cases reported annually, and 50% of these resulting in fatalities.
• Tobacco use is a major risk factor for head and neck cancers, with 230,000 cases linked to tobacco.
• The company's spokesperson emphasized that there is no connection between Biocon's product and the TGN1412 monoclonal antibody being tested in London.
• The company's clinical trials for its product have involved a large number of patients, with several hundred participants in international trials.

Statistics:

• Estimated 700,000 new cancer cases in India annually.
• 50% of cancer cases in India result in fatalities.
• 230,000 cancer cases in India are linked to tobacco use.
• Several hundred patients have participated in international trials for Biocon's product.

Sources:

• PTI (Press Trust of India) report, April 17.
• Biocon spokesperson Paula Sengupta, interviewed on April 17. (Note: The original report does not provide a full citation, but Paulo Sengupta is identified as the company spokesperson in the article.)